Gesellschaft mit beschränkter Haftung

HEYCHARGE REMOVES A KEY BARRIER TO THE GLOBAL MASS ADOPTION OF ELECTRIC VEHICLES

Retrieved on: 
Tuesday, February 20, 2024

MUNICH, Feb. 20, 2024 /PRNewswire/ -- EV Charging technology company, HeyCharge, GmbH, announced today that the end of unreliable smart EV charging has finally arrived - removing what is perhaps the last significant barrier to the global massification of Electric Vehicles. 

Key Points: 
  • MUNICH, Feb. 20, 2024 /PRNewswire/ -- EV Charging technology company, HeyCharge, GmbH, announced today that the end of unreliable smart EV charging has finally arrived - removing what is perhaps the last significant barrier to the global massification of Electric Vehicles.
  • HEYCHARGE REMOVES A KEY BARRIER TO THE GLOBAL MASS ADOPTION OF ELECTRIC VEHICLES.
  • "Before HeyCharge, smart EV chargers provided a frustrating user experience in low or no internet connectivity environments," said HeyCharge CEO Chris Cardé.
  • "Our mission is mass EV inclusivity, which means EV charging needs to be reliable everywhere from lower level parking garages to remote regions.

HEYCHARGE REMOVES A KEY BARRIER TO THE GLOBAL MASS ADOPTION OF ELECTRIC VEHICLES

Retrieved on: 
Tuesday, February 20, 2024

MUNICH, Feb. 20, 2024 /PRNewswire/ -- EV Charging technology company, HeyCharge, GmbH, announced today that the end of unreliable smart EV charging has finally arrived - removing what is perhaps the last significant barrier to the global massification of Electric Vehicles. 

Key Points: 
  • MUNICH, Feb. 20, 2024 /PRNewswire/ -- EV Charging technology company, HeyCharge, GmbH, announced today that the end of unreliable smart EV charging has finally arrived - removing what is perhaps the last significant barrier to the global massification of Electric Vehicles.
  • "Before HeyCharge, smart EV chargers provided a frustrating user experience in low or no internet connectivity environments," said HeyCharge CEO Chris Cardé.
  • "Our mission is mass EV inclusivity, which means EV charging needs to be reliable everywhere from lower level parking garages to remote regions.
  • HeyCharge's technology creates a 100% reliable EV charging universe free of no-to-low connectivity and network provider downtime.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.

EQS-News: FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced

Retrieved on: 
Friday, February 16, 2024

FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced

Key Points: 
  • FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced
    The issuer is solely responsible for the content of this announcement.
  • At the same time, the Company has announced a program to further increase competitiveness in Europe in light of a significantly weakening market environment.
  • Based on our preliminary business figures, we have therefore achieved all the targets we set for the fiscal year 2023."
  • The competitiveness program for Europe was announced against the background of the significant change in market conditions in Europe.

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

Retrieved on: 
Friday, February 16, 2024

TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).

Key Points: 
  • TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
  • Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
  • This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection.
  • The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin).

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group

Retrieved on: 
Monday, February 12, 2024

The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.

Key Points: 
  • The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.
  • Dr. Taehwan Kim, Managing Director of noul GmbH said, "noul GmbH will play a pivotal role in global malaria diagnosis through its activities as a member of the Swiss Malaria Group.
  • Swiss Malaria Group said, "Noul's innovative diagnostic tools align perfectly with the Swiss Malaria Group's emphasis on innovative solutions in the fight against malaria.
  • Noul, which focuses on diagnostic solutions in blood and tissue diagnostics, has developed a cutting-edge digital microscopy-based malaria diagnostic tool, miLab™ MAL."

B2C Mobility Sharing Global Industry Research Report 2024: Advanced Connectivity and Evolving Urbanization Trends Fueling Demand - Long-term Forecasts to 2028 and 2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 9, 2024

The "B2C Mobility Sharing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "B2C Mobility Sharing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global b2c mobility sharing market is expected to see exponential growth in the next few years.
  • Approximately 45% of vehicles now feature some level of advanced connectivity, a trend that bolsters the B2C mobility sharing landscape.
  • Key Service Models: The diverse offerings within the B2C mobility sharing market, including car sharing, bike sharing, scooter sharing, and ride-hailing services.

Breakthrough: Sono Motors GmbH’s Insolvency Plan Confirmed by Court and Investor Deal Concluded

Retrieved on: 
Wednesday, February 7, 2024

The first tranche of the investment from Yorkville was funded on February 6, 2024, and the remaining formal actions required for Sono Motors GmbH’s exit from its self-administration proceedings are expected to be concluded by February 29, 2024.

Key Points: 
  • The first tranche of the investment from Yorkville was funded on February 6, 2024, and the remaining formal actions required for Sono Motors GmbH’s exit from its self-administration proceedings are expected to be concluded by February 29, 2024.
  • Denis Azhar added: "Sono Motors GmbH will continue to pioneer solar in mobility with the vision to enable a world without fossil fuels.
  • Sono Motors GmbH believes that its innovative assets position the company for future success and extend its market position in solar mobility.
  • Sono Motors GmbH remains committed to solar-based, sustainable transportation solutions and its main objective of contributing to the mobility transition.